Oxford Instruments PLC
4 April 2001
Release Date: 7.30am, 4 April 2001
Year end update
Following its financial year end, Oxford Instruments plc, the advanced
instrumentation company, issues a year end update including its preliminary
unaudited orders and turnover figures for the year ended 31 March 2001.
Preliminary estimates of orders and turnover for the year to 31 March 2001,
excluding Oxford Instruments' share of the OMT joint venture, are £199 million
(2000 - £169 million) and £181 million (2000 - £161 million) respectively. The
turnover of OMT, the joint venture with Siemens, is estimated at £99 million
(2000 - £100 million). Operating profit before exceptional items for
continuing businesses is expected to be within the range of market
expectations.
In line with company forecasts, turnover from the Medical business increased
in the second half of the year following the earlier site relocation. The
major part of the Analytical business was also successfully consolidated onto
one site in March 2001. Of the three major sites now vacated, two are under
offer. This completes the management and site restructuring programme
initiated under the 'TopFlight' banner in September 1999 across the UK-based
businesses. The planned savings have been achieved, while continued investment
in the improvement programmes set up over the past 18 months is also
contributing progressively to operational efficiencies.
The successful launch last summer of a world-leading magnet for use in
biological research and drug development has already been followed by the
receipt of multiple orders worth several million pounds for this product.
Furthermore, the total number of overdue projects in the Superconductivity
business has been reduced by a further 30% in the past 6 months and progress
has been made with the delivery of a number of old unprofitable technically
challenging 'legacy contracts' which have been holding back the recovery of
the business.
In addition to the magnet orders above, the increase in new orders over the
past year has been driven primarily by the strength of the semiconductor and
telecommunications industries. These two sectors were responsible for around
20% of orders in 2000/01. While order levels from other markets have also held
up well, the company is cautious over the possible impact on future growth of
current trends in the major world economies. However, with second half orders
last year of around £107 million, the company enters 2001/02 with a record
order book. Moreover, it is committed to realising further operational
improvements in the coming year from the programmes already in place now that
site relocations are complete.
Andrew Mackintosh, Chief Executive of Oxford Instruments plc, said:
'I am pleased with the way the company has performed following the
restructuring started in 1999. The solid base we have created will aid our
continued recovery.'
Enquiries contact:
Andrew Mackintosh, Oxford Instruments plc Tel: 01865 881437
Martin Lamaison, Oxford Instruments plc Tel: 01865 881437
Toby Mountford, Citigate Dewe Rogerson Tel: 020 7282 2901
Melanie York, Citigate Dewe Rogerson Tel: 020 7282 2907
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.